Ignite Creation Date:
2024-05-06 @ 9:37 AM
Last Modification Date:
2024-10-26 @ 12:16 PM
Study NCT ID:
NCT03020992
Status:
COMPLETED
Last Update Posted:
2021-02-09
First Post:
2017-01-11
Brief Title:
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis AU Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
Multicenter Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis C-VIEW
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
C-VIEW
Brief Summary:
The purpose of the study is to demonstrate the effect of Certolizumab Pegol CZP treatment on the reduction of Anterior Uveitis AU flares in subjects with active axial Spondyloarthritis axSpA and a documented history of AU
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-000343-14 | EUDRACT_NUMBER | None | None |